Clinical Trial

Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma

Study acronym: TD-NEOE3V3
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of neoadjuvant toripalimab in combination with nab-paclitaxel and platinum versus neoadjuvant docetaxel in combination with cisplatin and 5-fluorouracil (DCF) in the treatment of resectable locally advanced esophageal squamous cell carcinoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-28.
Trial Details
NCT Number NCT06952621
Lead Sponsor Tang-Du Hospital
Conditions Esophageal Squamous Cell Carcinoma (ESCC)
Enrollment 390 participants
Start Date 2026-02-01
Primary Completion 2027-12-28 (estimated)
Study Completion 2028-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-30